ClearPoint Neuro Aktie News

Positive regulatorische Fortschritte des BioPharma-Partners und frühe Erfolge bei der Expansion der Plattform für fokussierte Ultraschalltechnologie SOLANA BEACH, CA / ACCESS Newswire / 3. August 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (das "Unternehmen"), ein globales Geräte-, Zell- und Gentherapie-ermöglichendes Unternehmen, das präzise Navigation zum Gehirn und zur Wirbelsäule anbietet, ...

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulate...

Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global d...

ClearPoint Neuro NASDAQ: CLPT reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line.

Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 202...

SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha ® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States. The Velocity ...

SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 first quarter on Wednesday, May 13th, after the market close. Investors and analysts are invited to listen to th...